Close window icon

3 INDICATIONS Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.

Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.

Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet's Disease. Read less

Read less

Otezla is the first and only oral therapy approved across all severities of adult plaque psoriasis SEE THE DATA

DOWNLOADABLE RESOURCES

Explore resources to help start your patients on Otezla and support them through their office visits or telemedicine calls

Starting Your Patients

  • Thumbnail image of the Otezla SupportPlus Request Form

    OTEZLA SUPPORTPLUS™
    REQUEST FORM

    Use this form if you need Otezla SupportPlus™ to assist you with prescription triage, benefit investigation, prior authorization (PA), or appeals support

  • Thumbnail image of the Otezla Specialty Pharmacy Start Form

    OTEZLA SPECIALTY
    PHARMACY START FORM

    If you prefer to work directly with a specialty pharmacy, you can e-scribe or use the Otezla Specialty Pharmacy Start Form

  • Thumbnail image of Otezla Prior Authorization (PA) Checklist

    OTEZLA PRIOR AUTHORIZATION CHECKLIST

    A resource to help organize PA information and potential documentation requirements

  • Thumbnail image of an Otezla Letter of Medical Necessity

    LETTER OF MEDICAL NECESSITY
     

    Assistance with appealing a coverage denial for an Otezla prescription

  • Thumbnail image of an Otezla Letter of Medical Necessity in Spanish

    LETTER OF MEDICAL NECESSITY
    (SPANISH VERSION)

    Assistance with appealing a coverage denial for an Otezla prescription

  • Thumbnail image of Otezla Specialty Pharmacy List

    OTEZLA SPECIALTY PHARMACY RESOURCE
     

    Download a list of specialty pharmacies that can process Otezla

 

Telemedicine Resources

The use of telemedicine and remote care services to treat patients has been increasing over time; in some situations, it may be essential. Here are a few telemedicine and remote care resources that you may find valuable:

Disclaimer: These links are being provided as a convenience and for informational purposes only; they do not constitute an endorsement or an approval by Amgen of any of the products, services, or opinions of the organization or individual. Amgen bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links.

 

HCP Resources

  • Thumbnail image of Otezla Full Prescribing Information

    PRESCRIBING
    INFORMATION

    Otezla Prescribing Information

 

Patient Resources

  • Otezla patient roadmap

    OTEZLA PATIENT
    ROADMAP

    A one-page guide to help new patients successfully start Otezla

  • Thumbnail image of Dual Starter Copay Support Information Sheet

    OTEZLA PATIENT STARTER SHEET

    Co-pay and support information for patients recently prescribed Otezla for plaque psoriasis or PsA

  • Thumbnail image of Otezla Co-Pay Support Starter Kit

    OTEZLA
    STARTER KIT

    Helpful information on getting started, Otezla delivery, patient stories, side effects, and support for your plaque psoriasis or PsA patients

  • Thumbnail image of the Plaque Psoriasis Symptom Tracker

    PLAQUE PSORIASIS SYMPTOM TRACKER

    30-day daily symptom tracker for plaque psoriasis

  • Thumbnail image of Psoriatic Arthritis (PsA) Symptom Tracker

    PsA SYMPTOM
    TRACKER

    30-day daily symptom tracker for PsA

 

PsA, psoriatic arthritis.

close button

Accordion icon

IMPORTANT SAFETY INFORMATION

Contraindications

  • Otezla is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation

Warnings and Precautions

  • Hypersensitivity: Hypersensitivity reactions, including angioedema and anaphylaxis, have been reported during postmarketing surveillance. If signs or symptoms of serious hypersensitivity reactions occur, discontinue Otezla and institute appropriate therapy
  • Diarrhea, Nausea, and Vomiting: Cases of severe diarrhea, nausea, and vomiting were associated with the use of Otezla. Most events occurred within the first few weeks of treatment. In some cases, patients were hospitalized. Patients 65 years of age or older and patients taking medications that can lead to volume depletion or hypotension may be at a higher risk of complications from severe diarrhea, nausea, or vomiting. Monitor patients who are more susceptible to complications of diarrhea or vomiting; advise patients to contact their healthcare provider. Consider Otezla dose reduction or suspension if patients develop severe diarrhea, nausea, or vomiting
  • Depression: Carefully weigh the risks and benefits of treatment with Otezla for patients with a history of depression and/or suicidal thoughts/behavior, or in patients who develop such symptoms while on Otezla. Patients, caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes, and they should contact their healthcare provider if such changes occur
    • Plaque Psoriasis: Treatment with Otezla is associated with an increase in depression. During clinical trials in patients with moderate to severe plaque psoriasis, 1.3% (12/920) of patients reported depression compared to 0.4% (2/506) on placebo. Depression was reported as serious in 0.1% (1/1308) of patients exposed to Otezla, compared to none in placebo-treated patients (0/506). Suicidal behavior was observed in 0.1% (1/1308) of patients on Otezla, compared to 0.2% (1/506) on placebo. One patient treated with Otezla attempted suicide; one patient on placebo committed suicide
    • Psoriatic Arthritis: Treatment with Otezla is associated with an increase in depression. During clinical trials, 1.0% (10/998) reported depression or depressed mood compared to 0.8% (4/495) treated with placebo. Suicidal ideation and behavior was observed in 0.2% (3/1441) of patients on Otezla, compared to none in placebo-treated patients. Depression was reported as serious in 0.2% (3/1441) of patients exposed to Otezla, compared to none in placebo-treated patients (0/495). Two patients who received placebo committed suicide compared to none on Otezla
    • Behçet’s Disease: Treatment with Otezla is associated with an increase in depression. During the clinical trial, 1% (1/104) reported depression or depressed mood compared to 1% (1/103) treated with placebo. No instances of suicidal ideation or behavior were reported in patients treated with Otezla or treated with placebo
  • Weight Decrease: Monitor body weight regularly; evaluate unexplained or clinically significant weight loss, and consider discontinuation of Otezla
    • Plaque Psoriasis: Body weight loss of 5-10% occurred in 12% (96/784) of patients with moderate to severe plaque psoriasis treated with Otezla and in 5% (19/382) of patients treated with placebo. Body weight loss of ≥10% occurred in 2% (16/784) of patients treated with Otezla compared to 1% (3/382) of patients treated with placebo
    • Psoriatic Arthritis: Body weight loss of 5-10% was reported in 10% (49/497) of patients taking Otezla and in 3.3% (16/495) of patients taking placebo
    • Behçet’s Disease: Body weight loss of >5% was reported in 4.9% (5/103) of patients taking Otezla and in 3.9% (4/102) of patients taking placebo
  • Drug Interactions: Apremilast exposure was decreased when Otezla was co-administered with rifampin, a strong CYP450 enzyme inducer; loss of Otezla efficacy may occur. Concomitant use of Otezla with CYP450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended

Adverse Reactions

  • Plaque Psoriasis: The most common adverse reactions (≥5%) are diarrhea, nausea, upper respiratory tract infection, and headache, including tension headache. Overall, the safety profile of Otezla in patients with mild to moderate plaque psoriasis was consistent with the safety profile previously established in adult patients with moderate to severe plaque psoriasis
  • Psoriatic Arthritis: The most common adverse reactions (≥5%) are diarrhea, nausea, and headache
  • Behçet’s Disease: The most common adverse reactions (≥10%) are diarrhea, nausea, headache, and upper respiratory tract infection

Use in Specific Populations

  • Otezla has not been studied in pregnant women. Advise pregnant women of the potential risk of fetal loss

Please click here for the full Prescribing Information.

INDICATIONS

Otezla® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.

Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.

Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.